On February 26, 2021, Artiva Biotherapeutics, Inc. closed the transaction. The company raised funding led by by new investor Venrock Healthcare Capital Partners, a fund managed by Venrock. The transaction included participation from other new investors Acuta Capital Partners LLC, Cormorant Asset Management, LLC, EcoR1 Capital, LLC, Janus Henderson Group plc (NYSE:JHG), Franklin Templeton Investment Management Limited, Logos Capital LLC, Surveyor Capital Management, Wellington Management Company LLP, RTW Venture Fund Limited (LSE:RTW), a fund managed by RTW Investments, LP, an undisclosed leading global investment firm, returning investors 5AM Venture Management, LLC, RA Capital Management, L.P., venBio LLC, along with strategic partners Green Cross Holdings Corporation (KOSE:A005250) and Green Cross Lab Cell Corporation (KOSDAQ:A144510).

The transaction included participation from 27 investors pursuant to exemption provided under regulation D.